Clearmind Medicine Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CMND.CN research report →
Companywww.clearmindmedicine.com
Clearmind Medicine Inc. , a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors.
- CEO
- Adi Zuloff-Shani
- IPO
- 2018
- HQ
- Vancouver, BC, CA
Price Chart
Valuation
- Market Cap
- $5.07M
- P/E
- -0.04
- P/S
- 0.00
- P/B
- 0.04
- EV/EBITDA
- 1.25
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -211.90%
- ROIC
- -114.59%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-11,627,302 · -23.55%
- EPS
- $-57.42 · 73.56%
- Op Income
- $-8,501,720
- FCF YoY
- -23.77%
Performance & Tape
- 52W High
- $63.90
- 52W Low
- $1.60
- 50D MA
- $2.07
- 200D MA
- $8.90
- Beta
- 1.56
- Avg Volume
- 3.60K
Get TickerSpark's AI analysis on CMND.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our CMND.CN Coverage
We haven't published any research on CMND.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CMND.CN Report →